IL-10 gene expression was significantly decreased in the tumor antigen-loaded DCs plus lenalidomide combination therapy groups compared with the PBS control group, suggesting the tumor antigen-loaded DCs plus lenalidomide combination therapy suppressed the production of inhibitory cytokine IL-10 in mouse tumors. The gene discussed is IL10; the disease is neoplasm.